Jean-Phillip Okhovat, MD
Internal Medicine · :Lone Tree
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 3
- Since medical school
- 12 years
- Graduated 2014
Offices
3 locations
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Okhovat’s office to ask if they take your plan before you enroll.
State licence records
1 licence
- Maryland D0087162Physician · since 2019 · expires 2027-09-30Specialty on the licence: DermatologyTold the state board they are not board certified.ActiveNo board action on this licenceCheck it with the state
We check Colorado, Delaware, Florida, Illinois, Maryland, New Jersey, New York, Tennessee, Texas, Virginia, Washington, plus California above. A state that is not in this list has not been checked, which is not the same as clear.
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 75.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Original Medicare doctor bills
$4,642
Medicare paid this office $4,642 for 105 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Short return visit (20+ min) | 41 | $1,430 | $35 |
| Biopsy of related skin growth, first growth | 17 | $782 | $46 |
| Destruction of precancer skin growth, 1 growth | 24 | $205 | $9 |
| Destruction of precancer skin growth, 2-14 growths | 17 | $205 | $2 |
| New patient visit (30+ min) | 21 | $140 | $7 |
Procedures year by year
| Procedure | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Destruction of precancer skin growth, 2-14 growths | – | – | – | – | 1,078 | 91 |
| Biopsy of related skin growth, first growth | – | – | – | – | 340 | 17 |
| Destruction of precancer skin growth, 1 growth | – | – | – | – | 291 | 24 |
| Biopsy of related skin growth, each additional growth | – | – | – | – | 203 | – |
| Destruction of precancer skin growth, 15 or more growths | – | – | – | – | 68 | – |
| Destruction of skin growth, 1-14 growths | – | – | – | – | 45 | – |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
105 Original Medicare patients in 2024. Average age 75 · Women 57% · Health risk score 1.08. Above the middle of the specialty; the typical dermatology clinician is at 1.01.
Conditions among them: High blood pressure 62% · Coronary heart disease 24% · Atrial fibrillation 18% · Chronic kidney disease 17% · Cancer 17% · Diabetes 15% · Depression 15% · COPD 13%.
The office billed $55,643, Medicare allowed $15,824 and paid $4,642; for 250 services of 20 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 105 | 250 | 75 | 1.08 | $55,643 | $4,642 |
| 2023 | 793 | 3,366 | 74 | 0.98 | $976,572 | $185,297 |
| 2022 | 11 | 11 | 73 | 3.04 | $4,569 | $1,718 |
| 2021 | 90 | 90 | 73 | 2.67 | $88,945 | $13,580 |
| 2020 | 122 | 124 | 74 | 2.46 | $150,961 | $18,129 |
| 2019 | 65 | 66 | 73 | 2.24 | $62,218 | $7,817 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 19 services
| Biopsy of related skin growth, first growth | 317 | $28,144 | $83 |
| New patient visit (30+ min) | 302 | $25,520 | $85 |
| Short return visit (20+ min) | 299 | $25,080 | $72 |
| New patient visit (45+ min) | 100 | $13,168 | $132 |
| Destruction of precancer skin growth, 1 growth | 269 | $12,101 | $42 |
| Return visit (30+ min) | 100 | $11,550 | $104 |
| Destruction of precancer skin growth, 15 or more growths | 63 | $9,490 | $140 |
| Biopsy of related skin growth, each additional growth | 116 | $8,576 | $42 |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | 27 | $6,802 | $243 |
| Destruction of precancer skin growth, 2-14 growths | 203 | $6,084 | $6 |
| Short return visit | 104 | $5,253 | $47 |
| Destruction of skin growth, 1-14 growths | 41 | $4,236 | $94 |
| Removal of cancer skin growth of body, arms, or legs, 1.1-2.0 cm | 35 | $4,154 | $104 |
| Complicated repair of wound of trunk, 2.6-7.5 cm | 12 | $4,060 | $338 |
| Destruction of cancer skin growth of trunk, arms, or legs, 1.1-2.0 cm | 16 | $2,655 | $140 |
| New patient visit (15+ min) | 38 | $1,989 | $52 |
| Punch biopsy, first skin growth | 15 | $1,935 | $108 |
| Removal of cancer skin growth of body, arms, or legs, 2.1-3.0 cm | 13 | $1,771 | $136 |
| Biopsy of ear | 23 | $1,683 | $65 |
2021: 2 services
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 67 | $10,397 | $155 |
| Initial hospital observation care per day, typically 70 minutes | 18 | $2,604 | $145 |
2020: 2 services
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 76 | $12,805 | $166 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 37 | $4,150 | $112 |
2019: 2 services
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 34 | $3,824 | $112 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 15 | $2,359 | $157 |
Medicaid work
$6,663 in 2024
Medicaid paid $6,663 for 78 billed services this clinician did in 2024, up to 23 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Telephone evaluation and management service by a physician or other qualified health care professional who may report evaluation and management services provided to an established patient, parent, or guardian not originating from a related E/M service provided within the previous 7 days nor leading to an E/M service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of medical discussion | 66 | $4,333 |
| Short return visit (20+ min) | 12 | $2,330 |
| 2024 | 78 | 2 | 23 | $6,663 |
Drugs they prescribed that Part D paid
$95,673
Pharmacies billed $95,673 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 424) in 2024. At or below the middle of the specialty; the typical dermatology clinician is at 0%.
357 generic and fewer than 11 brand-name prescriptions · $95,673 in drug cost · 49 antibiotic prescriptions to 47 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Tacrolimus | 14 | $1,097 | $78 |
| Fluorouracil | 19 | $1,055 | $56 |
| Ketoconazole | 37 | $645 | $17 |
| Triamcinolone Acetonide | 48 | $391 | $8 |
| Nitrofurantoin Mono-Macro | 20 | $180 | $9 |
See all 7 drugs
| Tacrolimus | 14 | $1,097 | $78 |
| Fluorouracil | 19 | $1,055 | $56 |
| Ketoconazole | 37 | $645 | $17 |
| Triamcinolone Acetonide | 48 | $391 | $8 |
| Nitrofurantoin Mono-Macro | 20 | $180 | $9 |
| Mupirocin | 11 | $46 | $4 |
| Paxlovid | 18 | $0 | $0 |
Year by year
| 2024 | 424 | 247 | 0% (0) | None | $95,673 |
| 2023 | 838 | 473 | 0% (0) | 10% | $59,688 |
| 2022 | 381 | 114 | 0% (0) | None | $311,431 |
| 2021 | 382 | 127 | 0% (0) | 13% | $368,119 |
| 2020 | 389 | 137 | 0% (0) | 19% | $394,091 |
| 2019 | 63 | 29 | 0% (0) | None | $8,856 |
| 2018 | 46 | 19 | 0% (0) | 28% | $3,497 |
| 2017 | 27 | None | None | None | $2,472 |
| 2016 | 29 | None | 0% (0) | 0% | $219 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 17 drugs
| Tacrolimus | 43 | $6,235 | $145 |
| Fluorouracil | 76 | $5,938 | $78 |
| Azelaic Acid | 33 | $3,257 | $99 |
| Metronidazole | 34 | $1,881 | $55 |
| Ketoconazole | 92 | $1,810 | $20 |
| Fluocinonide | 33 | $1,692 | $51 |
| Desonide | 25 | $1,571 | $63 |
| Clobetasol Propionate | 18 | $1,332 | $74 |
| Triamcinolone Acetonide | 144 | $1,176 | $8 |
| Tretinoin | 16 | $996 | $62 |
| Clindamycin Phosphate | 27 | $894 | $33 |
| Doxycycline Hyclate | 31 | $543 | $18 |
| Paxlovid (Eua) | 38 | $367 | $10 |
| Mupirocin | 38 | $280 | $7 |
| Lagevrio (Eua) | 25 | $258 | $10 |
| Hydrocortisone | 41 | $179 | $4 |
| Cephalexin | 16 | $60 | $4 |
2022: 10 drugs
| Cosentyx Pen (2 Pens) | 12 | $74,546 | $6,212 |
| Dupixent | 13 | $41,940 | $3,226 |
| Clobetasol Propionate | 23 | $1,337 | $58 |
| Clindamycin Phosphate | 18 | $1,264 | $70 |
| Triamcinolone Acetonide | 55 | $970 | $18 |
| Ketoconazole | 34 | $928 | $27 |
| Tretinoin | 12 | $927 | $77 |
| Doxycycline Hyclate | 17 | $733 | $43 |
| Ciclopirox | 14 | $362 | $26 |
| Hydrocortisone | 26 | $131 | $5 |
2021: 10 drugs
| Cosentyx Pen (2 Pens) | 12 | $69,809 | $5,817 |
| Clobetasol Propionate | 32 | $1,962 | $61 |
| Tretinoin | 14 | $1,261 | $90 |
| Ketoconazole | 36 | $1,203 | $33 |
| Triamcinolone Acetonide | 56 | $1,109 | $20 |
| Fluocinonide | 16 | $1,083 | $68 |
| Fluorouracil | 12 | $919 | $77 |
| Ammonium Lactate | 27 | $637 | $24 |
| Ciclopirox | 11 | $340 | $31 |
| Mupirocin | 13 | $68 | $5 |
2020: 11 drugs
| Clobetasol Propionate | 34 | $3,417 | $100 |
| Betamethasone Diprop Augmented | 22 | $1,259 | $57 |
| Ketoconazole | 40 | $1,172 | $29 |
| Fluocinonide | 11 | $1,157 | $105 |
| Tretinoin | 19 | $1,069 | $56 |
| Triamcinolone Acetonide | 53 | $674 | $13 |
| Clindamycin Phosphate | 11 | $560 | $51 |
| Doxycycline Hyclate | 13 | $426 | $33 |
| Hydroxyzine | 18 | $412 | $23 |
| Ammonium Lactate | 12 | $153 | $13 |
| Hydrocortisone | 11 | $134 | $12 |
2019: 1 drug
| Hydroxyzine | 12 | $209 | $17 |
Money from drug and device companies
$102 in 2023
| 2023 | 4 | 6 | None | $102 |
| 2019 | 2 | 2 | None | $114 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| E.R. Squibb & Sons L.L.C. | Sotyktu | $45 | 2 payments
|
| Incyte | Opzelura | $26 | 2 payments
|
| Abbvie | Skyrizi | $17 | 1 payment
|
| Lilly USA | Taltz | $14 | 1 payment
|
See all 6 published payments
| Lilly USA | Meals · 2023-09-27 | Taltz | $14 |
| E.R. Squibb & Sons L.L.C. | Meals · 2023-09-20 | Sotyktu | $30 |
| Incyte | Meals · 2023-09-19 | Opzelura | $13 |
| Incyte | Meals · 2023-08-25 | Opzelura | $13 |
| E.R. Squibb & Sons L.L.C. | Meals · 2023-08-03 | Sotyktu | $14 |
| Abbvie | Meals · 2023-06-15 | Skyrizi | $17 |
See earlier years (2019)
2019: $114
| Ortho Dermatologics a division of Bausch Health US | Duobrii | $96 | 1 payment
|
| LEO Pharma | Enstilar | $18 | 1 payment
|
Professional record
- NPI
- 1497103105
- Licence
- MD D87162Maryland D0087162: Active
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Internal medicine (207R00000X); Federal specialty code 207N00000X (207N00000X)
- Mailing address
- 325 Distel Cir, Los Altos, CA, 94022
- NPI first listed
- 2016-06-03
- NPI last updated
- 2026-01-06
- NPI record certified
- 2026-01-06
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 1 Scobee Cir Ste 3, Plymouth, MA, 02360
This office lists an electronic records connection.